A new study has revealed that low-dose aspirin therapy could reduce the risk of atherosclerotic events in people suffering from type 2 diabetes that also have mild renal dysfunction .
The research, by scientists in Japan and published in Diabetes Care, monitored 2,523 patients that were randomly put into two separate groups, with the first group receiving either 81 or 100 mg levels of aspirin each day, while the other group received no aspirin at all.
The scientists reviewed the groups for an average of 4.37 years, with fatal and non-fatal atherosclerotic ischemic heart disease, stroke and peripheral arterial disease being the primary end points in patients.
They found a significant interaction between aspirin and mild renal dysfunction, and for the 1,373 patients with glomerular filtration rate (eGFR), the primary end point incidence was much lower in the aspirin group than in the group that didn’t take aspirin. The incidence of primary end points was not affected by aspirin therapy in patients with an eGFR of less than 60 mL/min/1.73 m² or in those patients with an eGFR more than or equal to 90 mL/min/1.73 m².
The researchers commented “The current study demonstrated that low-dose aspirin therapy reduced the risk of atherosclerotic events in type 2 diabetic patients with eGFR 60 to 89 mL/min/1.73 m². The results suggest that eGFR may be useful for risk stratification in the primary prevention strategy with aspirin.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…